Evidence map›Paper›PMID 11850851›Full record

ArticleOncogene2002

Monoclonal antibodies raised against Xenopus p53 interact with human p73.

Morgane Le Bras, Valérie Delattre, Karim Bensaad, Giovanni Blandino, Thierry Soussi

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Morgane Le BrasLaboratoire de Génotoxicologie des Tumeurs, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
Valérie Delattre
Karim Bensaad
Giovanni Blandino
Thierry Soussi
Institut Curie · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. The structure of the p63 and p73 genes is quite similar, but both have common activities with p53, such as DNA binding and transactivation. Both p53 and p73 bind to mdm2, but only p53 is degraded through the activity of mdm2. p63 neither binds to nor is degraded by mdm2 despite important conservation in the key interacting residues. Using a panel of monoclonal antibodies raised against human and Xenopus p53, we have been able to find several antibodies that cross-react strongly with human p73. These antibodies react both with exogenous p73 expressed in mammalian cells and with endogenous p73. Interestingly, all these antibodies react with the same epitope localized in the amino-terminus of p53, but have no cross-reaction with p63. This epitope corresponds to the exact mdm2 binding site to p53. These antibodies inhibit the interaction between either p53 or p73 and mdm2, and may be useful tools for the study of these proteins. Furthermore, our studies suggest that there exist specific spatial requirements for the interaction between p53 or p73 and mdm2.

Indexed as

Antibody SpecificityMembrane ProteinsXenopus ProteinsAmino Acid SequenceAnimalsAntibodies, MonoclonalAutoantibodiesBlotting, WesternCross ReactionsDNA-Binding ProteinsFluorescent Antibody Technique, IndirectGenes, Tumor SuppressorHumansImmune SeraMolecular Sequence DataNuclear ProteinsAntibodies, MonoclonalAutoantibodiesCKAP4 protein, humanDNA-Binding ProteinsImmune SeraMembrane ProteinsNuclear ProteinsPhosphoproteinsRecombinant ProteinsTP63 protein, humanTP63 protein, XenopusTP73 protein, humanTrans-ActivatorsTranscription FactorsTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor ProteinsXenopus Proteins

Identifiers

PMID11850851
OpenAlexW2321878531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.